AANEM News Express

AANEM News Express

Science News: Critical Illness Polyneuropathy, Myopathy and Neuronal Biomarkers in COVID-19 Patients: A Prospective Study

12/15/2021
 
Submitted by: Elliot Bodofsky, MD
Edited by: Milvia Y. Pleitez, MD

Frithiof R, Rostami E, Kumlien E, et al. Critical illness polyneuropathy, myopathy and neuronal biomarkers in COVID-19 patients: A prospective study. Clin Neurophysiol. 2021;132(7):1733-1740. doi:10.1016/j.clinph.2021.03.016

Summary: This article determines the risk factors for developing critical illness neuropathy (CIN) and/or myopathy (CIM) in 111 COVID patients admitted to an ICU in Sweden, as well as differences between COVID and non-COVID patients with ICU weakness. There were 14 COVID patients with ICU weakness, and 10 in the non-COVID group. All patients received upper and lower extremity nerve conduction testing, needle EMG, and blood tests for three biomarkers for neuronal injury. The biomarkers were also compared to a group of COVID ICU patients that did not develop weakness. 
 
Of the 14 COVID ICU patients with weakness, 11 met the EMG/NCS criteria for CIN and/or CIM. All of the CIN/CIM patients were male (p=.01), and overall CIN/CIM COVID patients had a higher body mass index than those that did not (35 vs. 28, p=.006). CIN/CIM patients had a far longer stay in the ICU (27 days vs. 7) and a higher incidence of thromboembolic events, vasopressor support, and renal insufficiency. In fact, a majority of COVID patients intubated for more than 2 weeks developed CIN/CIM. Comparing COVID ICU weakness against non-COVID ICU weakness, COVID patients were more often male, and had a higher incidence of neuropathy, (CIN) but not CIM. All biomarkers for neuronal injury were higher in the COVID CIN/CIM group than non-CIN/CIM, and all correlated well with the degree of neuropathy seen on NCS.

Comments: This study shows that CIN/CIM is common in COVID patients that require prolonged intubation, those with more complications, and are male. Biomarkers for neuronal injury are good screening tests and correlate well with NCS. A limitation to this study was the modest number of patients with CIN/CIM. The article provides importance guidance on which COVID ICU patients are at risk for CIN/CIM, and patients that require evaluation.

Similar Article: Critical illness myopathy and polyneuropathy in Covid-19: Is it a distinct entity?Tankisi H.Clin Neurophysiol. 2021 Jul;132(7):1716-1717. 


View Related News Stories:

  EducationScience NewsNSEB


Recent AANEM News

Remembering George Kraft, MD, MS

The American Clinical Neurophysiology Society to Hold Another Townhall Meeting of Clinical Neurophysiology, Epilepsy, and Neuromuscular Fellowship Program Directors

Science News: Amyotrophic Lateral Sclerosis and Noninvasive Positive Pressure Ventilatory Support: "Nasal Noninvasive Ventilation" or "Noninvasive Ventilatory Support"?

CMS Finalizes Updates to Physician Fee Schedule

Advocacy in Action: State Liaison Leads the Way for Patient Advocacy in Washington and Beyond





Advertisement

ABEM

Advertisement

Donate

Advertisement